Learning Objectives:

1. Compare and contrast serum tumor markers such as protein biomarkers, circulating tumor cells (CTC) and fragmented cell-free DNA (circulating tumor DNA or ctDNA)

2. Describe examples of current and emerging uses of ctDNA in selected malignancies

3. Discuss emerging uses of ctDNA in lymphoid malignancies for treatment monitoring, identification of residual disease, and identification of actionable mutations

and

Learning Objectives:

1. To review the mechanisms of immune checkpoint inhibition and the rationale for combined therapy

2. To review the efficacy and toxicities of dual checkpoint blockade in melanoma as a rationale for studies of modified regimens

3. To present the current data around modified regimens in melanoma to inform future combination strategies in melanoma and other solid tumors